MedImmune/Wyeth FluMist
Executive Summary
MedImmune's intranasal flu vaccine FluMist receives recommendation from Advisory Committee on Immunization Practices Sept. 25 for use in healthy people ages 5 to 49 years of age. MedImmune has shipped 2.4 mil. doses to date; Wyeth's DTC ad campaign is underway (1"The Pink Sheet" Sept. 22, 2003, p. 16)...
You may also be interested in...
FluMist Reimbursement Is Ahead Of Plan; TV Ads Will Begin Sept. 29
The initial coverage decisions for the FluMist nasal flu vaccine indicate that MedImmune and Wyeth will be able to maintain the $46 per dose price of the vaccine
QUOTED. 2 March 2021. Michael Coyle.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: